ARRIVENT BIOPHARMA, INC.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 45.3% | 45.3% | -42.5% |
| FY2024 | -31.2% | -31.2% | -29.3% |
| FY2025 | -54.1% | -54.1% | -49.9% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 45.3% | 45.3% | -42.5% |
| FY2024 | -31.2% | -31.2% | -29.3% |
| FY2025 | -54.1% | -54.1% | -49.9% |